Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois. more
Time Frame | ETON | Sector | S&P500 |
---|---|---|---|
1-Week Return | 11.93% | 0.31% | -1.26% |
1-Month Return | 5.34% | 0.6% | -4.16% |
3-Month Return | 63.86% | -9.44% | -0.46% |
6-Month Return | 301.8% | -5.15% | 3.58% |
1-Year Return | 228.12% | 0.33% | 22.47% |
3-Year Return | 233% | 4.53% | 25.13% |
5-Year Return | 86.39% | 35.98% | 77.7% |
10-Year Return | 114.72% | 100.72% | 190.12% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 959.00K | 39.00K | 21.83M | 21.25M | 31.64M | [{"date":"2019-12-31","value":3.03,"profit":true},{"date":"2020-12-31","value":0.12,"profit":true},{"date":"2021-12-31","value":69,"profit":true},{"date":"2022-12-31","value":67.16,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 453.00K | 286.00K | 2.62M | 6.93M | 10.58M | [{"date":"2019-12-31","value":4.28,"profit":true},{"date":"2020-12-31","value":2.7,"profit":true},{"date":"2021-12-31","value":24.79,"profit":true},{"date":"2022-12-31","value":65.52,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 506.00K | (247.00K) | 19.21M | 14.32M | 21.06M | [{"date":"2019-12-31","value":2.4,"profit":true},{"date":"2020-12-31","value":-1.17,"profit":false},{"date":"2021-12-31","value":91.21,"profit":true},{"date":"2022-12-31","value":67.98,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 52.76% | (633.33%) | 87.99% | 67.38% | 66.56% | [{"date":"2019-12-31","value":59.97,"profit":true},{"date":"2020-12-31","value":-719.82,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":76.58,"profit":true},{"date":"2023-12-31","value":75.65,"profit":true}] |
Operating Expenses | 19.11M | 26.86M | 20.70M | 22.58M | 22.25M | [{"date":"2019-12-31","value":71.12,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":77.07,"profit":true},{"date":"2022-12-31","value":84.05,"profit":true},{"date":"2023-12-31","value":82.84,"profit":true}] |
Operating Income | (18.60M) | (27.11M) | (1.50M) | (8.26M) | (1.19M) | [{"date":"2019-12-31","value":-1860100000,"profit":false},{"date":"2020-12-31","value":-2711100000,"profit":false},{"date":"2021-12-31","value":-149500000,"profit":false},{"date":"2022-12-31","value":-826000000,"profit":false},{"date":"2023-12-31","value":-119200000,"profit":false}] |
Total Non-Operating Income/Expense | 562.00K | (1.72M) | (1.47M) | (1.52M) | 1.01M | [{"date":"2019-12-31","value":55.86,"profit":true},{"date":"2020-12-31","value":-170.78,"profit":false},{"date":"2021-12-31","value":-145.73,"profit":false},{"date":"2022-12-31","value":-151.29,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (18.32M) | (27.97M) | (1.96M) | (9.02M) | (689.00K) | [{"date":"2019-12-31","value":-1832000000,"profit":false},{"date":"2020-12-31","value":-2797000000,"profit":false},{"date":"2021-12-31","value":-195500000,"profit":false},{"date":"2022-12-31","value":-902100000,"profit":false},{"date":"2023-12-31","value":-68900000,"profit":false}] |
Income Taxes | (281.00K) | 859.00K | 1.01M | 761.00K | 247.00K | [{"date":"2019-12-31","value":-27.93,"profit":false},{"date":"2020-12-31","value":85.39,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":75.65,"profit":true},{"date":"2023-12-31","value":24.55,"profit":true}] |
Income After Taxes | (18.04M) | (28.83M) | (2.96M) | (9.78M) | (936.00K) | [{"date":"2019-12-31","value":-1803900000,"profit":false},{"date":"2020-12-31","value":-2882900000,"profit":false},{"date":"2021-12-31","value":-296100000,"profit":false},{"date":"2022-12-31","value":-978200000,"profit":false},{"date":"2023-12-31","value":-93600000,"profit":false}] |
Income From Continuous Operations | (18.32M) | (27.97M) | (1.96M) | (9.02M) | (936.00K) | [{"date":"2019-12-31","value":-1832000000,"profit":false},{"date":"2020-12-31","value":-2797000000,"profit":false},{"date":"2021-12-31","value":-195500000,"profit":false},{"date":"2022-12-31","value":-902100000,"profit":false},{"date":"2023-12-31","value":-93600000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (18.04M) | (28.83M) | (2.96M) | (9.78M) | (936.00K) | [{"date":"2019-12-31","value":-1803900000,"profit":false},{"date":"2020-12-31","value":-2882900000,"profit":false},{"date":"2021-12-31","value":-296100000,"profit":false},{"date":"2022-12-31","value":-978200000,"profit":false},{"date":"2023-12-31","value":-93600000,"profit":false}] |
EPS (Diluted) | (1.03) | (1.36) | (0.11) | (0.35) | (0.06) | [{"date":"2019-12-31","value":-103,"profit":false},{"date":"2020-12-31","value":-136,"profit":false},{"date":"2021-12-31","value":-11,"profit":false},{"date":"2022-12-31","value":-35,"profit":false},{"date":"2023-12-31","value":-6,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ETON | |
---|---|
Cash Ratio | 1.03 |
Current Ratio | 1.51 |
Quick Ratio | 1.41 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ETON | |
---|---|
ROA (LTM) | -12.50% |
ROE (LTM) | -44.30% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ETON | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.55 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.45 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ETON | |
---|---|
Trailing PE | NM |
Forward PE | 36.90 |
P/S (TTM) | 11.62 |
P/B | 22.82 |
Price/FCF | 219 |
EV/R | 10.06 |
EV/Ebitda | 51.26 |
Eton Pharmaceuticals Inc (ETON) share price today is $13.42
Yes, Indians can buy shares of Eton Pharmaceuticals Inc (ETON) on Vested. To buy Eton Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ETON stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Eton Pharmaceuticals Inc (ETON) via the Vested app. You can start investing in Eton Pharmaceuticals Inc (ETON) with a minimum investment of $1.
You can invest in shares of Eton Pharmaceuticals Inc (ETON) via Vested in three simple steps:
The 52-week high price of Eton Pharmaceuticals Inc (ETON) is $15. The 52-week low price of Eton Pharmaceuticals Inc (ETON) is $3.03.
The price-to-earnings (P/E) ratio of Eton Pharmaceuticals Inc (ETON) is
The price-to-book (P/B) ratio of Eton Pharmaceuticals Inc (ETON) is 22.82
The dividend yield of Eton Pharmaceuticals Inc (ETON) is 0.00%
The market capitalization of Eton Pharmaceuticals Inc (ETON) is $349.61M
The stock symbol (or ticker) of Eton Pharmaceuticals Inc is ETON